Upturn in Temporary Drug Safety Staff Augmentation
The number of pharmaceutical companies and contract research organizations seeking additional drug safety expertise on a project or temporary basis is up marketwide, according to Klein Hersh International, a leading placement firm in the life sciences industry.
“Our company has seen significant growth in this area, and the momentum continues as companies scramble for talent who can plug gaps and meet deadlines,” said Klein Hersh Director of Drug Safety and EpidemiologyDan Strauss. “Our expertise in this market means we are in a prime position to quickly add experienced consultants to our clients’ teams, and also help other organizations that need interim talent within drug safety.”
In response to the growth in this segment, Klein Hersh is adding pharmacovigilance physicians and other drug development personnel to its available resources.
“We are mirroring what we’re seeing in the marketplace and ramping up,” Strauss said. “This is not a trend that we envision ending anytime soon.”
Strauss said the upturn may be part of a broader business trend toward using contract employees.
“For a lot of companies, it would be a significant drain on payroll to employ permanent, high-level team members who are qualified to assess product viability, review adverse events or oversee safety surveillance,” Strauss said. “However, by providing these companies with drug safety expertise only when they really need it most, Klein Hersh ensures that everybody wins.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
